<p>HUA MEDICINE-B (02552.HK) announced its 2025 annual results, with revenue of RMB 493 million, an increase of 92.6% year-on-year. It recorded a net profit of RMB 1.106 billion, compared to a loss of RMB 250 million in the previous year, turning from loss to profit; earnings per share were RMB 1.12. No final dividend was declared</p>

159849

159506

159837

<p>HUA MEDICINE-B announced its 2025 annual results, with revenue of 493 million RMB, an increase of 92.6% year-on-year. It recorded a net profit of 1.106 billion RMB, compared to a loss of 250 million RMB in the previous year, turning from loss to profit; earnings per share were 1.12 RMB. No final dividend is declared</p>

AASTOCKS

China Merchants CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Guotai CSI Bio-medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

HUA MEDICINE-B

"Performance" HUA MEDICINE's annual net profit is 1.106 billion RMB, turning losses into profits